Manufacturer of Controlled Substances: Notice of Application, 44285-44286 [2010-18474]
Download as PDF
<![CDATA[
44285
Federal Register / Vol. 75, No. 144 / Wednesday, July 28, 2010 / Notices
Drug
Schedule
Methylphenidate (1724) ................
Fentanyl (9801) ............................
Oxycodone (9143) ........................
Hydromorphone (9150) ................
Dated: July 19, 2010.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Registration
By Notice dated April 20, 2010, and
published in the Federal Register on
April 26, 2010, (75 FR 21661), Almac
Clinical Services Inc., (ACSI), 2661
Audubon Road, Audubon, Pennsylvania
19403, made application by renewal to
the Drug Enforcement Administration
(DEA) to be registered as an importer of
the basic classes of controlled
substances listed in schedule II:
The company plans to import the
listed controlled substances to
manufacture bulk controlled substance
intermediates for sale to its customers.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and 952(a)
and determined that the registration of
Penick Corporation to import the basic
classes of controlled substances is
consistent with the public interest and
with United States obligations under
international treaties, conventions, or
protocols in effect on May 1, 1971, at
this time. DEA has investigated Penick
Corporation to ensure that the
company’s registration is consistent
with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 952(a)
and 958(a), and in accordance with 21
CFR 1301.34, the above named company
is granted registration as an importer of
the basic classes of controlled
substances listed.
Dated: July 19, 2010.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
Dated: July 19, 2010.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2010–18475 Filed 7–27–10; 8:45 am]
[FR Doc. 2010–18476 Filed 7–27–10; 8:45 am]
Drug Enforcement Administration
BILLING CODE 4410–09–P
By Notice dated April 26, 2010 and
published in the Federal Register on
April 30, 2010, (75 FR 22844), Penick
Corporation, 33 Industrial Park Road,
Pennsville, New Jersey 08070, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as an importer of the basic
classes of controlled substances listed in
schedule II:
Drug
Schedule
Coca Leaves (9040) .....................
Opium, raw (9600) .......................
Poppy Straw (9650) .....................
Concentrate of Poppy Straw
(9670).
PO 00000
Frm 00072
Fmt 4703
Sfmt 4703
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Manufacturer of Controlled
Substances: Notice of Application
Importer of Controlled Substances:
Notice of Registration
DEPARTMENT OF JUSTICE
sroberts on DSKD5P82C1PROD with NOTICES
The company plans to import small
quantities of the listed controlled
substances in dosage form to conduct
clinical trials.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and 952(a),
and determined that the registration of
Almac Clinical Services Inc. (ACSI) to
import the basic classes of controlled
substances is consistent with the public
interest, and with United States
obligations under international treaties,
conventions, or protocols in effect on
May 1, 1971, at this time. DEA has
investigated Almac Clinical Services
Inc. (ACSI) to ensure that the company’s
registration is consistent with the public
interest. The investigation has included
inspection and testing of the company’s
physical security systems, verification
of the company’s compliance with state
and local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 952(a)
and 958(a), and in accordance with 21
CFR 1301.34, the above named company
is granted registration as an importer of
the basic classes of controlled
substances listed.
Drug Enforcement Administration
BILLING CODE 4410–09–P
Jkt 220001
II
II
II
DEPARTMENT OF JUSTICE
[FR Doc. 2010–18486 Filed 7–27–10; 8:45 am]
19:05 Jul 27, 2010
Schedule
Oxycodone (9143) ........................
Hydromorphone (9150) ................
Fentanyl (9801) ............................
II
II
II
II
The company plans to import the
listed controlled substances in finished
dosage form (FDF) from foreign sources
for analytical testing and clinical trials
in which the foreign FDF will be
compared to the company’s own
domestically-manufactured FDF. This
analysis is required to allow the
company to export domesticallymanufactured FDF to foreign markets.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and 952(a),
and determined that the registration of
Mylan Pharmaceuticals Inc., to import
the basic classes of controlled
substances is consistent with the public
interest, and with United States
obligations under international treaties,
conventions, or protocols in effect on
May 1, 1971, at this time. DEA has
investigated Mylan Pharmaceuticals
Inc., to ensure that the company’s
registration is consistent with the public
interest. The investigation has included
inspection and testing of the company’s
physical security systems, verification
of the company’s compliance with state
and local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 952(a)
and 958(a), and in accordance with 21
CFR 1301.34, the above named company
is granted registration as an importer of
the basic classes of controlled
substances listed.
VerDate Mar<15>2010
Drug
II
II
II
II
Pursuant to § 1301.33(a) of Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on January 27, 2009,
Johnson Matthey Pharmaceutical
Materials, Inc., Pharmaceuticals Service,
25 Patton Road, Devens, Massachusetts
01434, made application to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the basic classes of controlled
substances listed in schedule II:
Drug
Amphetamine (1100) ....................
Methylphenidate (1724) ................
Nabilone (7379) ............................
Alfentanil (9737) ...........................
Sufentanil (9740) ..........................
Remifentanil (9739) ......................
Hydrocodone (9193) .....................
Schedule
II
II
II
II
II
II
II
The company plans to utilize this
facility to manufacture small quantities
E:\FR\FM\28JYN1.SGM
28JYN1
44286
Federal Register / Vol. 75, No. 144 / Wednesday, July 28, 2010 / Notices
of the listed controlled substances in
bulk and to conduct analytical testing in
support of the company’s primary
manufacturing facility in West Deptford,
New Jersey. The controlled substances
manufactured in bulk at this facility will
be distributed to the company’s
customers.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substances,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than September 27, 2010.
Dated: July 19, 2010.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration
By Notice dated March 5, 2010, and
published in the Federal Register on
March 19, 2010, (75 FR 13304), Halo
Pharmaceutical Inc., 30 North Jefferson
Road, Whippany, New Jersey 07981,
made application by renewal to the
Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of the basic classes of
controlled substances listed in
schedules I and II:
Drug
Schedule
Dihydromorphine (9145) ...............
Hydromorphone (9150) ................
sroberts on DSKD5P82C1PROD with NOTICES
[FR Doc. 2010–18500 Filed 7–27–10; 8:45 am]
DEPARTMENT OF JUSTICE
BILLING CODE 4410–09–P
I
II
Dihydromorphine is an intermediate
in the manufacture of Hydromorphone
and is not for commercial distribution.
The company plans to manufacture
Hydromorphone HCL for sale to other
manufacturers and for the manufacture
of other controlled substance dosage
units for distribution to its customers.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of Halo
Pharmaceutical Inc., to manufacture the
listed basic classes of controlled
substances is consistent with the public
19:05 Jul 27, 2010
Dated: July 19, 2010.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
BILLING CODE 4410–09–P
[FR Doc. 2010–18474 Filed 7–27–10; 8:45 am]
VerDate Mar<15>2010
interest at this time. DEA has
investigated Halo Pharmaceutical Inc.,
to ensure that the company’s
registration is consistent with the public
interest. The investigation has included
inspection and testing of the company’s
physical security systems, verification
of the company’s compliance with state
and local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
Jkt 220001
By Notice dated March 16, 2010, and
published in the Federal Register on
March 24, 2010, (75 FR 14190), Sigma
Aldrich Research Biochemicals, Inc.,
1–3 Strathmore Road, Natick,
Massachusetts 01760–2447, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the basic classes of controlled
substances listed in schedules I and II:
Drug
Schedule
Cathinone (1235) ..........................
Methcathinone (1237) ..................
Aminorex (1585) ...........................
Alpha-ethyltryptamine (7249) .......
Lysergic acid diethylamide (7315)
Tetrahydrocannabinols (7370) .....
4-Bromo-2,5dimethoxyamphetamine (7391).
4-Bromo-2,5dimethoxyphenethylamine
(7392).
2,5-Dimethoxyamphetamine
(7396).
3,4-Methylenedioxyamphetamine
(7400).
N-Hydroxy-3,4methylenedioxyamphetamine
(7402).
3,4-Methylenedioxy-Nethylamphetamine (7404).
3,4Methylenedioxymethamphetamine (MDMA) (7405).
Psilocybin (7437) ..........................
5-Methoxy-N,Ndiisopropyltryptamine (7439).
PO 00000
Frm 00073
Fmt 4703
Sfmt 9990
I
I
I
I
I
I
I
I
I
I
I
I
I
Drug
1-[1-(2Thienyl)cyclohexyl]piperidine
(TCP) (7470).
N-Benzylpiperazine (BZP) (7493)
Heroin (9200) ...............................
Normorphine (9313) .....................
Amphetamine (1100) ....................
Methamphetamine (1105) ............
Nabilone (7379) ............................
1-Phenylcyclohexylamine (7460)
Phencyclidine (7471) ....................
Cocaine (9041) .............................
Codeine (9050) .............................
Diprenorphine (9058) ...................
Ecgonine (9180) ...........................
Levomethorphan (9210) ...............
Levorphanol (9220) ......................
Meperidine (9230) ........................
Metazocine (9240) ........................
Methadone (9250) ........................
Morphine (9300) ...........................
Thebaine (9333) ...........................
Levo-alphacetylmethadol (9648) ..
Remifentanil (9739) ......................
Carfentanil (9743) .........................
Fentanyl (9801) ............................
Schedule
I
I
I
I
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
The company plans to manufacture
reference standards.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Sigma Aldrich Research Biochemicals,
Inc., to manufacture the listed basic
classes of controlled substances is
consistent with the public interest at
this time. DEA has investigated Sigma
Aldrich Research Biochemicals, Inc., to
ensure that the company’s registration is
consistent with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
Dated: July 19, 2010.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2010–18495 Filed 7–27–10; 8:45 am]
BILLING CODE 4410–09–P
I
I
E:\FR\FM\28JYN1.SGM
28JYN1
]]>Agencies
[Federal Register Volume 75, Number 144 (Wednesday, July 28, 2010)]
[Notices]
[Pages 44285-44286]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-18474]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances: Notice of Application
Pursuant to Sec. 1301.33(a) of Title 21 of the Code of Federal
Regulations (CFR), this is notice that on January 27, 2009, Johnson
Matthey Pharmaceutical Materials, Inc., Pharmaceuticals Service, 25
Patton Road, Devens, Massachusetts 01434, made application to the Drug
Enforcement Administration (DEA) to be registered as a bulk
manufacturer of the basic classes of controlled substances listed in
schedule II:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Amphetamine (1100)......................... II
Methylphenidate (1724)..................... II
Nabilone (7379)............................ II
Alfentanil (9737).......................... II
Sufentanil (9740).......................... II
Remifentanil (9739)........................ II
Hydrocodone (9193)......................... II
------------------------------------------------------------------------
The company plans to utilize this facility to manufacture small
quantities
[[Page 44286]]
of the listed controlled substances in bulk and to conduct analytical
testing in support of the company's primary manufacturing facility in
West Deptford, New Jersey. The controlled substances manufactured in
bulk at this facility will be distributed to the company's customers.
Any other such applicant, and any person who is presently
registered with DEA to manufacture such substances, may file comments
or objections to the issuance of the proposed registration pursuant to
21 CFR 1301.33(a).
Any such written comments or objections should be addressed, in
quintuplicate, to the Drug Enforcement Administration, Office of
Diversion Control, Federal Register Representative (ODL), 8701
Morrissette Drive, Springfield, Virginia 22152; and must be filed no
later than September 27, 2010.
Dated: July 19, 2010.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 2010-18474 Filed 7-27-10; 8:45 am]
BILLING CODE 4410-09-P
